Afexa Life Sciences Inc (FXA.TO) said it was encouraged by the interim analysis of a study carried out to assess the effectiveness and safety of its Cold-FX flu remedy in children. The randomized, placebo-controlled study, performed by an independent data monitoring committee, will determine if Cold-FX helps reduce cold and flu symptoms in children. The committee recommended that the study continue into the 2011/2012 cold and flu season. The Cold-FX website currently does not recommend the use of the product in children under the age of 12.
Source
